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Abstract
The COVID-19 global pandemic is a threat not only to the health of millions of individu-
als, but also to the stability of infrastructure and economies around the world. The disease 
will inevitably place an overwhelming burden on healthcare systems that cannot be effec-
tively dealt with by existing facilities or responses based on conventional approaches. We 
believe that a rigorous clinical and societal response can only be mounted by using intel-
ligence derived from a variety of data sources to better utilize scarce healthcare resources, 
provide personalized patient management plans, inform policy, and expedite clinical trials. 
In this paper, we introduce five of the most important challenges in responding to COVID-
19 and show how each of them can be addressed by recent developments in machine learn-
ing (ML) and artificial intelligence (AI). We argue that the integration of these techniques 
into local, national, and international healthcare systems will save lives, and propose spe-
cific methods by which implementation can happen swiftly and efficiently. We offer to 
extend these resources and knowledge to assist policymakers seeking to implement these 
techniques.
Keywords Clinical decision support · Healthcare · COVID-19
1 Introduction
Both the UK and the international community have seen an unbelievable amount of pres-
sure put on their social and healthcare infrastructure over the past months. AI and machine 
learning can use data to make objective and informed recommendations, and can help 
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ensure that scarce resources are allocated as efficiently as possible. Doing so will save lives 
and can help reduce the burden on healthcare systems and professionals.
This paper goes into detail about specific practical challenges faced by healthcare sys-
tems, and how AI and machine learning can improve decision-making to ensure the best 
outcomes possible. While the paper is primarily focused on the UK national healthcare 
system, the challenges and methods highlighted in the paper apply to other countries. 
First, AI and machine learning can help us identify people who are at highest risk of being 
infected by the novel coronavirus. This can be done by integrating electronic health record 
data with a multitude of “big data” pertaining to human-to-human interactions (from cel-
lular operators, traffic, airlines, social media, etc.). This will make allocation of resources 
like testing kits more efficient, as well as informing how we, as a society, respond to this 
crisis over time. AI and machine learning can also help us work out which infected patients 
are more likely to suffer more severely from COVID-19. We can provide more accurate 
patient risk scores that will help clinical professionals decide who needs urgent treatment 
(and resources), and when.
Secondly, COVID-19 symptoms and disease evolution vary widely from patient to 
patient in terms of severity and characteristics. A one-size-fits-all approach for treatment 
doesn’t work. We also are a long way off from mass-producing a vaccine. Machine learn-
ing techniques can help determine the most efficient course of treatment for each individual 
patient on the basis of observational data about previous patients, including their character-
istics and treatments administered. We can use machine learning to answer key “what-if” 
questions about each patient, such as “What if we postpone a couple hours before putting 
them on a ventilator?” or “Would the outcome for this patient be better if we switched them 
from supportive care to an experimental treatment earlier?”
Third, we have seen a large variety of approaches taken by decision-makers when 
deciding on policies to respond to COVID-19. This is true from the individual level (i.e. 
practitioners) all the way up to the government level. For example, differences in triaging 
protocols used by medical institutions and practitioners could mean that two patients with 
similar profiles will end up receiving different types of treatment depending on where they 
happen to live. It is hard to get a clear sense of which decisions result in the best outcomes. 
In such a stressful situation, it is also hard for decision-makers to be aware of the outcomes 
of decisions being made by their counterparts elsewhere. Once again, data-driven AI and 
machine learning can provide objective and usable insights that far exceed the capabili-
ties of existing methods. We can gain valuable insight into what the differences between 
policies are, why policies are different, which policies work better, and how to design and 
adopt improved policies. This information can be shared between decision-makers at all 
levels, improving consistency and efficiency across the board. The result is that routine 
decisions can be made in a more coordinated and timely way, freeing up valuable medical 
attention to the cases that demand real-time expertise.
Fourth, randomized clinical trials (RCTs) are generally used to judge the relative effec-
tiveness of a new treatment. However, these trials can be slow and costly, and may fail to 
uncover specific subgroups for which a treatment may be most effective. A specific prob-
lem posed by COVID-19 is that subjects selected for RCTs tend not to be elderly, or to 
have other conditions; as we know, COVID-19 has a particularly severe impact on both 
those patient groups.
Rather than recruiting and assigning subjects at random, machine learning methods can 
recruit subjects from identifiable subgroups, and assign them to treatment or control groups 
in a way that speeds up learning. These methods have been shown to significantly reduce 
error and achieve a prescribed level of confidence in findings, while also requiring fewer 
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subjects. We can also use machine learning to target particular treatments to specific sub-
groups and to understand what treatments are suitable for the population as a whole.
These four practical challenges form the key research avenues that we discuss in more 
detail in Sect. 2, whose focus is not to provide solutions but rather outline some of the key 
opportunities for the machine learning and AI researchers to contribute to the containment 
of the Covid-19 pandemic
In addition to the aforementioned practical challenges, the COVID-19 pandemic 
inspires various other research threads that are rather underdeveloped in existing litera-
ture. In particular, because we still know very little about the COVID-19 pandemic, and 
the virus itself may continue to change over time, we may not be able to rely on the data 
from decisions and outcomes taken in other countries, as those may generalize poorly to 
different countries. In the meantime, unproven hypotheses about the disease are likely to 
propagate online, impacting individual behaviour and causing systemic risks. This encour-
ages more progress in an area of machine learning called transfer learning to account for 
differences between populations, substantially eliminating bias while still extracting usable 
data that can be applied from one population to another. In addition, we need methods to 
make us aware of the degree of uncertainty of any given conclusion or recommendation 
generated from machine learning. This means that decision-makers can be provided with 
confidence estimates that tell them how confident they can be about a recommended course 
of action. We discuss these research challenges in Sect. 3.
1.1  Practical challenges
1.1.1  Managing limited healthcare resources
Healthcare systems in the UK and elsewhere in the world will soon face a severe scarcity 
of resources—in particular testing kits, hospital beds, ICU beds, ventilators and personnel. 
The UK, for example, currently has capacity for only a limited amount of tests to be con-
ducted per day (https ://www.wired .co.uk/artic le/coron aviru s-testi ng-uk) and many of the 
intensive care unit (ICU) beds are already occupied (https ://www.indep enden t.co.uk/news/
healt h/coron aviru s-europ e-inten sive-care-beds-venti lator sa940 3981.html). This scarcity of 
resources is aggravated by the fact that individuals with COVID19 are known to experi-
ence widely different patterns of disease progression and outcomes: while some patients 
are asymptomatic, others manifest flu-like symptoms of varying severity, and some experi-
ence complications such as pneumonia and fatal multi-organ failure (Jiang et  al. 2020). 
Since resources are limited and risk and disease progression so heterogeneous, it is crucial 
to identify—as early as possible—which individuals are likely to have been infected by the 
virus, which infected individuals may experience adverse events, which types of medical 
resources those individuals will require, and when these resources will be required.
The scarcity of healthcare resources will be exacerbated by the need to employ those 
resources to deal with both COVID-19 cases and with other patients who require—or will 
require—medical care. There is thus a clear and urgent need to deploy systems that can 
provide early warnings for personalized risk and disease progression of individuals, and 
that can inform medical personnel and healthcare systems about which patients would ben-
efit from what resources and when (https ://www.nytim es.com/2020/03/21/us/coron aviru 
s-medic al-ratio ning.html).
How AI can help
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Mature AI-based support systems for a number of chronic diseases already exist, but 
a pandemic such as COVID19 presents a problem of a different nature. While chronic 
diseases jeopardize individual health, pandemics jeopardize public health because they 
present both individual and systemic risks. Pandemics, by nature, undermine the underly-
ing social structures that connect individuals together. Dealing with these systemic risks 
requires merging clinical data with a variety of diverse social data. Electronic health 
records (EHR) hold data that can be used to pinpoint individuals’ clinical risk factors 
(Wang et al. 2020), and which can be linked to the multitude of “big data” pertaining to 
human-to-human interactions (e.g. data from cellular operators, traffic, airlines, and social 
media). Machine learning (ML) is especially suited for merging these various sources of 
data to issue accurate predictions of risk and help uncover the social structures through 
which systemic risks manifest and spread.
One of the strengths of ML is its ability to “learn” how an individual’s features (risk 
factors), including clinical and social information, can be mapped into personalized predic-
tions of risk (Alaa and van der Schaar 2018). While standard epidemiological approaches—
such as the Cox proportional hazards model—are unable to effectively combine data from 
diverse data sources and modalities (e.g. demographic, social, longitudinal, imaging, 
multi-omics), modern techniques for representation learning based on neural networks can 
readily and effectively learn from such diverse data to issue personalized predictions of risk 
as well as to update these predictions as features evolve over time. For instance, learning 
can be informed by dynamic models of social interaction (Alaa et al. 2018; Xu et al. 2014), 
and hence can predict the likelihood that an individual has been, or will be, in contact 
with a coronavirus carrier. This makes it possible to better allocate testing kits such that 
individuals most likely to have been exposed to the virus can be identified and tested most 
promptly. Such risk prediction mechanisms can be used for disease prevention, monitoring 
and detection.
With regard to individuals who have already been infected with SARS-CoV-2, it is 
important to be able to predict, on a personalized basis, the risk of experiencing adverse 
events (including mortality) as well as the specific healthcare resources a patient will/
might need, and the timing of these needs. Key factors determining risk include patient 
age and/or the existence of comorbidities, such as hypertension, cystic fibrosis, or 
immunosuppression associated with transplants and chemotherapy for cancer (Zhou 
et  al. 2020). However, the current risk-scoring methods for infected patients employ 
only a few factors such as Clinical Frailty Score, the number of comorbidities, or use of 
medication or administrative data from previous hospital admissions, to predict which 
patients are at highest risk. These relatively crude approaches (such as using the Charl-
son score (Goldstein et al. 2004)) may be appropriate in the frenetic acute stages of this 
epidemic, but they fail to capture and account for the subtle interactions between age, 
specific comorbidities (including their duration), organ failure scores and the impact of 
the wider determinants of health. Moreover, reliance on such measures may also result 
in failure to discover new risk factors—which may be especially important for a dis-
ease about which so little is known. Methods based on automated ML (Alaa and van 
der Schaar 2018; Lee et  al. 2019; Zhang et  al. 2020) can address both of these fail-
ings, offering increasingly accurate subtypings of the COVID-19 disease as more data 
is gathered, while simultaneously uncovering new risk factors as well as interactions 
among new and established risk factors.
Moreover, patients with severe comorbidities may experience diverse adverse events, 
especially because their usual treatments may be suspended in order to avoid compro-
mising their immune response. In these cases, ML methods for assessing competing 
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risks at the individual level– estimating the probabilities of a patient experiencing dif-
ferent adverse events and how these probabilities are changing over time—have shown 
improved prediction accuracy compared to conventional epidemiological methods ( 
Alaa and van der Schaar 2018). These methods can play an essential role in guiding 
decisions for individual patients.
As noted, patients diagnosed with COVID-19 experience a wide variety of disease 
trajectories and outcomes, such as heterogeneous incubation periods and variable rates 
of in-hospital pulmonary decline (Jiang et  al. 2020). As a consequence, risk assess-
ment must involve more than just a single time point prediction of final outcomes, and 
must also take account of the evolution of disease severity. This provides not only a way 
to predict a patient’s disease trajectory but—by including follow up data—it enables 
understanding of how specific events (e.g. symptoms worsening) may move patients 
from one trajectory or cluster/temporal phenotype to another. This is fundamental to the 
delivery of systems that allow the dynamic management of limited healthcare resources.
There are two routes by which resource allocation should be an active choice guided 
by AI-based risk assessment:
(a) Patient-level resource allocation concerning decisions made on an individual 
basis. This includes such decisions as who is most likely to benefit from early admission 
to an ICU, which patients can be safely stepped down from intensive support, or which 
patients can be safely discharged from the hospital and when.
Such questions of timely admission and discharge are often answered on the basis of 
simple rules of thumb (e.g. examining the most recent measurements for a select few 
variables, and making decisions based on threshold values). A more tailored approach 
to triaging should involve incorporating information from the individual patient’s his-
tory using all available observations at any point in time. Such triaging systems should 
be informed by state-of-the-art AI-based early warning systems trained on temporal 
(longitudinal) data. These AI-enabled systems have been developed and tested, and have 
shown their efficacy in practice (Yoon et al. 2016; Lee et al. 2018). They can anticipate 
a patient’s future healthcare needs, and can also handle irregularly collected data and 
impute missing features (Yoon et al. 2018a, b), as well as inferring important predictors 
of patient outcomes (e.g. specific comorbidities that are more likely to worsen the prog-
nosis of a COVID-19 patient) (Yoon et al. 2018; Jordon et al. 2018). Importantly, ML 
and AI approaches are well-suited for handling the irregularly-sampled temporal data 
common in this setting, employing mixtures of Gaussian processes (Alaa et al. 2017), 
recurrent neural networks (Lee et al. 2019), state-space models (Alaa et al. 2019), neural 
network-based point processes (Qian et al. 2020), Bayesian non-parametric approaches 
(Bellot and Schaar 2020).
(b) Measurement-level resource allocation (value of information). Making observations 
and collecting healthcare data is costly in terms of time, materials, and personnel—and not 
all data is equally valuable. We need to actively decide what we should measure, when it 
should be measured, and on which patients; making observations on each patient should 
be an active and informed process, so that the information gained can be most valuable. 
Developments in the field of active sensing offer tools for optimally trading off the value of 
information against the cost of acquisition (Yoon et al. 2019, 2018).
Taken together, techniques in patient- and measurement-level prediction and active 
sensing can integrate information across time in order to effectively allocate resources 
among patients while prioritizing measurements and treatments, thereby enabling institu-
tions to dynamically allocate hospital resources depending on their patients’ needs. This, 
in turn, allows physicians to make informed decisions to postpone treatment for conditions 
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that are not immediately life threatening, so that resources can be used for critically-ill 
COVID-19 patients.
1.2  Developing personalized patient management and treatment plans
Vaccines and therapeutics for COVID-19 will take some time to be developed and intro-
duced (Lu 2020). Although a number of antiviral medications are being trialed, none are 
currently known to be effective. Due to the heterogeneous nature of patient disease trajec-
tories, one-size-fits-all treatment plans (which are developed at the population level, rather 
than individualized patient level) are very likely to be ineffective in terms of both patient 
outcomes and use of limited resources. To save lives and effectively use scarce resources, it 
is therefore essential to develop management and treatment plans that are personalized for 
each patient, depending on their unique characteristics and needs.
How AI can help
AI-based models can efficiently use available observational data to learn the effects of 
existing treatments on individuals, given their specific features (characteristics) includ-
ing existing comorbidities. This can help identify the best management approach for each 
patient based on their features, including the best policies for employing mechanical venti-
lation and/or experimental treatments.
Learning personalized treatment effects can be carried out using recent advances in 
machine learning models tailored for learning in the observational data setting. Models 
based on Gaussian processes (Ahmed et al. 2017), generative adversarial networks (Yoon 
et al. 2018), and deep neural networks (Zhang et al. 2020) can learn individual-level effects 
of experimental treatments on the basis of observational data (without resorting to rand-
omized trials), and can potentially be integrated with omics data. Using such methods, we 
can identify patient subgroups for whom treatments such as Remdesivir, Lopinavir/Ritona-
vir and Chloroquine may be effective (Gao et al. 2020).
Learning personalized management and treatment plans requires modeling the evolu-
tion of a patient’s health state as they respond to different sequences of treatments and sup-
portive care over time during hospitalization. AI-based models (Ahmed et al. 2017; Yoon 
et al. 2018; Zhang et al. 2020) can answer what-if questions such as: “what would happen 
to a given patient if mechanical ventilation were delayed for a few hours?” or “what would 
a given patient’s outcomes be if we switched from supportive care to a specific experimen-
tal treatment a week earlier?”
Because each patient is different, answering counterfactual questions such as these 
requires efficient use of regularly-updated observational data from patients who have expe-
rienced different management plans since the beginning of the viral outbreak; this can help 
us learn what the best plan is for each individual given the available healthcare resources. 
The counterfactual questions under consideration here pertain not only to which interven-
tion should be applied for each patient, but also when the patient needs this intervention. 
This is especially relevant given the limited resources available.
Leveraging longitudinal patient observational data, the counterfactual recurrent network 
in Bica et al. (2020) learns to predict counterfactual health trajectories under different man-
agement plans for each individual. Such predictions can be made in a dynamic fashion by 
modeling and updating the patient’s state over time to account for information in all past 
medical events. Doing this can pinpoint a timeframe during which intervention would be 
most effective, as well as choosing the specific sequence of interventions that would result 
in the best outcome for each patient. In addition, this method has the potential to show 
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when scarce interventions—such as the mechanical ventilator—are not critically needed by 
a patient, and for how long their use can be postponed without the patient suffering signifi-
cant deterioration.
1.3  Informing policies and enabling effective collaboration
Governmental and local responses to the outbreak have been remarkably varied (Ferguson 
et al. 2020). At the national, regional, institutional and even individual practitioner level, 
very different decisions are being made in terms of prevention, diagnosis, treatment and 
disease management. In uncertain settings—like the ones presented by COVID-19—pol-
icymakers and clinical practitioners make different observations, take different measure-
ments, and act differently on the basis of evidence. For example, differences in triaging 
protocols across institutions and practitioners could mean that two patients with similar 
profiles end up receiving different courses of treatment simply because of where they hap-
pen to be seen.
There is little consensus as to what policies and decisions are most effective; as a result, 
there is substantial variation in efficiency of resource usage, quality of care, and patient 
outcomes. It is imperative that we employ systematic, data-driven methods in learning 
from the policies already implemented in the wild. Coordinating experiences across dif-
ferent actors allows us to more systematically quantify policies and their efficacies, thereby 
informing the design of improvements.
How AI can help
Evidence-based decision-making entails collecting costly observations about the effects 
of a treatment or resource allocation policy, and subsequently committing to an informed 
decision on the basis of accumulated observations. AI methods tackle the following impor-
tant and interrelated questions, and offer a common language through which healthcare 
practitioners can exchange information and improve policies over time.
What are the different diagnostic and treatment policies?
First, we can quantify the decision rules that underlie observed behavior (e.g. the 
guidelines and protocols often implicitly encoded in different institutions). For a concise, 
standardized description of behavior, what is learned here is an accessible mapping from 
information (e.g. patient characteristics and measurements) to actions (i.e. diagnostic tests 
and treatments)—a mapping that is immediately indicative of which individual actions are 
more or less likely to be taken in any given scenario. For instance, precisely how badly 
does a patient have to be doing before a ventilator is employed? How does this compare 
across hospitals? Modeling policies transparently enables identification and comparison of 
actions by different decision-makers.
What are the priorities demonstrated by different policies?
Second, we can quantify the preferences and potential biases implicit in observed 
behavior (e.g. what treatments are preferred ceteris paribus, and how time-sensitivity and 
monetary costs weigh on decisions). For a concise, standardized interpretation of different 
policies, what is obtained is an accessible mapping from behavior to preferences—a map-
ping that is immediately indicative of what aspects of the decision-making process (e.g. 
expense, accuracy, time pressure, and patient populations) appear more or less important 
for a given decisionmaker. For instance, we may expect that an institution diagnoses and 
treats older patients more quickly than younger ones. But do they actually? And if so, by 
how much?
What are the best improvements to existing policies?
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Third, we can quantify the efficacy of both new and existing policies, so as to iden-
tify the best policy to implement under different priorities and in different circumstances. 
While answering the two directly preceding questions can facilitate transparent comparison 
and understanding of variations in clinical practice, here the culminating objective is in 
the prescription of better diagnosis and treatment policies. This can be accomplished by 
integrating the results of answering both of the preceding questions with novel techniques 
in reinforcement learning to inform and instruct policy evaluation and policy improvement. 
For instance, knowing that we desire to optimize for a certain agreed-upon set of priorities, 
precisely what is the best decision rule to implement going forward?
What is the level of confidence in learned policies?
Finally, we can quantify the uncertainty involved in these tasks of identifying, under-
standing, and improving decisions and policies. This is critical in new environments where 
existing predictive expertise is lacking—such as in responding to COVID-19. For instance, 
novel diagnostic tests will certainly have errors, and the overall effectiveness of different 
treatments is not known a priori. Quantifying uncertainty permits a clear understanding of 
which components of our models we can have more confidence in, and which components 
we cannot. For instance, when can we confidently assert that a given action is necessary, 
and when does the choice require more nuanced deliberation?
In the presence of constraints on medical personnel, the potential for decision support 
through policy evaluation, improvement, and well-calibrated uncertainty estimates enables 
routine decisions to be taken in a more timely manner—thus freeing up valuable medical 
attention to the cases that warrant real-time expertise. Recent work in tackling some of 
these challenges involves quantifying and explaining behavior in the context of early diag-
nosis (Hüyük and Jarrett 2020), modeling and understanding sequential decisions under 
uncertain deadline pressure (Jarrett 2020), and learning interpretable parameterizations of 
behavior via counterfactual reasoning to highlight cost benefit tradeoffs associated with 
different actions over time (Bica et  al. 2020). There is, therefore, enormous opportunity 
for AI to facilitate healthcare professionals in making better decisions by learning from the 
“experimentation” currently taking place in different settings for different patients.
1.4  Expediting clinical trials
In order to compare the effectiveness of a new treatment to an existing one (or to a pla-
cebo), randomized clinical trials (RCTs) are considered the gold standard. However, it is 
a well-known fact that RCTs can be slow and costly, and may fail to uncover specific sub-
populations for which a treatment would be most effective. Moreover, conclusions drawn 
from RCTs are typically valid only for the types of patients recruited for that RCT. This is 
an especially significant problem in the case of COVID-19, as elderly patients and patients 
with comorbidities, who are known to be at higher risk, are typically excluded from RCTs.
How AI can help
Recent work on improving the design of adaptive clinical trials has demonstrated that 
both the efficiency and effectiveness of RCTs can be significantly enhanced through the 
application of ML (Zame et al. 2020).
While most RCTs simply allocate patients to treatment and control groups through 
uniform randomization, this procedure can be highly sub-optimal in terms of learn-
ing. ML-enabled adaptive clinical trials (Lee et  al. 2020; Atan et  al. 2019; Zame et  al. 
2020) can recruit patients in cohorts (rather than all at once), the effects on each cohort 
can be observed before recruiting the next cohort, and may be heterogeneous across 
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identifiable subgroups of patients (as would be expected for COVID-19 treatments). Rather 
than recruiting and assigning subjects at random, ML methods can recruit subjects from 
identifiable subgroups, and assign subjects to treatment or control groups in a way that 
speeds up learning. These methods have been shown to significantly reduce error and 
achieve a prescribed level of confidence in findings, while requiring many fewer patients.
Another important application of ML in the domain of RCTs is the post-hoc analysis of 
clinical trials, and, in particular, the identification of sub-populations that are most similar 
in characteristics (array of features) and treatment response. The identification of such sub 
populations is informative in itself because it permits inference about the extent of hetero-
geneity and response across the entire population. Moreover, quantifying the uncertainty 
associated with the treatment of specific sub-populations makes it easier to target particular 
treatments to those sub-populations and understand what treatments are suitable for the 
population as a whole.
2  Research challenges: accounting for uncertainty
Because it is novel, the COVID-19 pandemic is being managed with very limited prior 
experience and limited data. Our knowledge of its behavior is very uncertain (Anderson 
et  al. 2020). Moreover, since the coronavirus may undergo further natural selection and 
evolve geospatially as the pandemic progresses, understanding this evolution and the 
uncertainties that accompany it will be key to mitigation.
To work effectively within this environment, we need to quantify the degree of uncer-
tainty in our knowledge about the disease, and then apply this to understand the risks and 
benefits of the clinical and social policies employed to mitigate it. This is especially impor-
tant because unproven hypotheses about COVID-19 have already circulated rapidly online 
and through various media outlets, and are likely to impact individual behavior and hence 
affect systemic risks.
There are three particular sources of uncertainty encountered when dealing with the 
current COVID-19 pandemic. First, models trained using data from the population tested 
for SARS-CoV-2 may be biased, since patients who have been tested are not necessarily 
representative of the overall UK population. Relying on data from other countries (e.g. 
China, Italy, Iran or South Korea) where the outbreak took off earlier may lead to biased 
models that do not generalize well to the UK population. Second, there is a limited amount 
of data available about COVID-19 patients. In light of the vast heterogeneity of patient 
characteristics and outcomes   (Alaa et  al. 2020), blanket hypothesis tests about the dis-
ease may appear erroneously inconclusive. Finally, since risk predictors and indicators of 
COVID-19 outcomes are unknown, there is a great deal of uncertainty regarding the value 
of information conveyed in different national and patient-level factors.
How AI can help
ML techniques provide a wide variety of solutions for modeling uncertainty in these 
three settings:
The problem of biased models can be addressed via transfer learning methods, which 
implicitly cope with uncertainty in predictions made for individuals from populations 
other than those used for training. International collaboration could produce a large data-
set comprising data from multiple infected populations, and a single two-level risk assess-
ment model can be trained on such a dataset and deployed worldwide. However, since the 
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characteristics of the UK population differ from other populations (e.g. the median age 
in the UK is 40.5 years, whereas for Iran it is 31.3 years), the model needs to “learn” its 
uncertainty in predictions made for specific individuals in the UK. Transfer learning mod-
els, e.g., based on transductvie dropout (Chan et al. 2020), accomplish this task effectively, 
and have been previously shown to work well for prognostication of disease across differ-
ent countries or healthcare systems.
Transfer learning is relevant not only for transferring models across populations, but 
also for updating ML models for a single population as the diagnosed cohort evolves over 
time. Specifically, as diseases and populations evolve over time, observed distributions of 
patients—and their characteristics and outcomes—may change. Using successive batches 
of data as they arrive, scalable Bayesian optimization techniques have been developed to 
update models with new information for continued performance, while efficiently leverag-
ing past optimizations (Zhang et al. 2019).
Importantly, we need to know what we do know and what we do not know when pro-
viding decision-makers with actionable information based on AI-systems. For this, new 
technologies have been developed to systematically quantify uncertainty in the predictions 
made by machine learning models (Ahmed 2020; Alaa and van der Schaar 2020). We need 
to mandate that all predictions generated by AI-enabled systems for decision support also 
come with confidence estimates. Decision-makers will then know when and for which 
patients they can trust the predictions issued by the AI system, and when they cannot have 
the same degree of certainty.
Quantifying uncertainty on predictions of patient-level outcomes is crucial for guiding 
hospitalization and therapeutic decisions. It is also important that uncertainty measures 
provide guarantees on their coverage performance, i.e., the likelihood that a confidence 
interval covers the true outcome. Recently proposed methods based on influence functions 
enables obtaining Jackknife estimates of machine learning outcomes in a post-hoc fashion, 
i.e., it does not depend on the model architecture or design choices. These methods have 
been applied to both models of cross-sectional and longitudinal data (Ahmed 2020; Alaa 
and van der Schaar 2020).
Active sensing is another key area where uncertainty quantification can play a cruci-
cal role: by quantifying the reduction of uncertainty in patient-level predictions associated 
with different types of information, we can decide on which information to gather in order 
to build data sets that would further be used to train machine learning models. This can be 
achieved using recently proposed actor-critic methods for active sensing and estimation of 
value of information (Yoon et al. 2019, 2018).
3  Recommended means of implementing the techniques
For the variety of AI-based models discussed, deployment can take advantage of exist-
ing data infrastructure. Information about patients from EHR records, can be com-
bined—through collaboration between public and private sectors—with data from cel-
lular operators, airlines, traffic applications, and social media. Such collections of static 
and temporal data streams can be integrated by AI models to enable more personalized 
predictions of risk and treatment effects, patient management policies, and better trial 
design.
To illustrate what is possible, we will consider the UK. Countries with already exist-
ing virus surveillance systems, such as the UK, are in an excellent position to capitalize 
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on the available data and employ the aforementioned AI technologies to improve out-
comes. Recent emergency privacy legislation has allowed the collection, linkage and 
analysis of record-level, patient-identifiable data by the national health and social care 
data aggregator, NHS Digital. In addition, all COVID-19 testing data is collated nation-
ally by Public Health England, while patients suspected to have been infected are also 
triaged through a national health triage service, with the data from calls being made 
available in real time. Daily service-level reporting of resource utilization across the 
acute sector is being expanded, while similar capacity monitoring is being introduced 
across social care. Taken together, such nationally-collated datasets provide a fertile 
environment to implement the techniques outlined in this paper.
Implementation of proposed AI-based methods can be accomplished through three 
levels of human-machine interface:
(a) Individual-level interface. Based on individual health risk assessments issued by 
AI models, patients can be alerted to undergo testing via email, mobile phone calls, 
and text messages. GPS-powered mobile applications installed by individuals on their 
cell phones can be used to guide social distancing by notifying individuals in high-risk 
geographical locations where a significant number of COVID-19 cases have been diag-
nosed, or where a significant number of high risk potential carriers of the virus are cur-
rently present. Implementation of this system can be primarily based on software appli-
cations that can be promptly executed and linked to NHS-held GP patient registries.
(b) Hospital-level interface. For public health risk assessments, existing in-hospital 
EHR infrastructure can be complemented with risk-modeling applications that display 
and alert clinicians to the evolving risks of patients within each hospital. Existing tel-
ehealth applications adopted by the NHS’s Technology Enabled Care Services (TECS) 
program can be utilized for distant diagnosis and care for self-isolating individuals with 
evident symptoms. Implementation of AI-based models in hospitals can largely rely on 
existing hardware infrastructure to link input data streams from ICUs to software (pow-
ered by ML models) that displays patient risks to clinicians.
(c) Nation-level interface. Government officials and decision-makers can be sup-
ported with centralized applications that continuously update officials with the most 
recent epidemiological data on COVID-19, in addition to geographically-stratified 
aggregate risk assessments and hospital occupancy rates for the entire population. This 
can be directly linked to the NHS patient registration database, and would interface with 
the other applications to collect information on population risk. This can help officials 
make selective strategic decisions on which locations to lock down, and which hospitals 
need more resources.
In the UK, the National Health Service provides a centralized route to deployment for a 
whole country, while for example in the US, implementation may be most effective through 
large provider networks, HMOs or insurers. Figure 1 provides a high-level illustration of 
how the proposed ML and AI solutions can help healthcare systems respond to COVID-19.
We hope that a variety of safe and trustworthy machine learning methodologies will be 
developed and implemented worldwide to assist users (policymakers, clinicians, patients, 
etc.) in their decision-making processes.
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